-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pfizer and Myovant Sciences announced that Relugolix combination therapy may have "potential benefits" for the long-term treatment of patients with uterine fibroids.
The study reached its primary endpoint, that is, 78.
The study also reached three major secondary endpoints, including the two-year sustained remission rate, the time to recurrence of severe menstrual bleeding, and the rate of amenorrhea (amenorrhoea).
Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences, said: "We are very pleased to see the positive data from the LIBERTY study, which supports the potential benefits of long-term Relugolix combination therapy.
James Rusnak, senior vice president of global product development at Pfizer and chief development officer of internal medicine and hospitals, said: “Uterine fibroids may affect the life of many women and have uncomfortable symptoms such as menstrual bleeding.
The US Food and Drug Administration Administration ( the FDA ) is currently reviewing Relugolix combination therapy for uterine fibroids application, a decision is expected to be June 1, 2021.
Manage FDA
Original source:
Original source:href="" target="_blank" rel="noopener">in this message
